Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Free Cash Flow (2016 - 2026)

Lexaria Bioscience's Free Cash Flow history spans 12 years, with the latest figure at -$2.2 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$2.2 million for Q1 2026, down 47.19% from a year ago — trailing twelve months through Feb 2026 was -$9.4 million (down 26.39% YoY), and the annual figure for FY2025 was -$10.5 million, down 109.42%.
  • Free Cash Flow for Q1 2026 was -$2.2 million at Lexaria Bioscience, down from -$984098.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$619614.0 in Q1 2024 to a low of -$3.6 million in Q2 2025.
  • The 5-year median for Free Cash Flow is -$1.3 million (2022), against an average of -$1.7 million.
  • Peak annual rise in Free Cash Flow hit 64.22% in 2025, while the deepest fall reached 183.08% in 2025.
  • Year by year, Free Cash Flow stood at -$1.3 million in 2022, then rose by 6.65% to -$1.2 million in 2023, then plummeted by 132.78% to -$2.8 million in 2024, then surged by 64.22% to -$984098.0 in 2025, then tumbled by 124.03% to -$2.2 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.2 million, -$984098.0, and -$2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.